383 related articles for article (PubMed ID: 34637693)
1. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches.
Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S
J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693
[TBL] [Abstract][Full Text] [Related]
2. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
Mishra A; Rathore AS
Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
[TBL] [Abstract][Full Text] [Related]
4. Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches.
Rehman HM; Sajjad M; Ali MA; Gul R; Naveed M; Aslam MS; Shinwari K; Bhinder MA; Ghani MU; Saleem M; Rather MA; Ahmad I; Amin A
Int J Biol Macromol; 2023 May; 237():124169. PubMed ID: 36990409
[TBL] [Abstract][Full Text] [Related]
5.
Patil SM; Martiz RM; Ramu R; Shirahatti PS; Prakash A; Chandra S J; Ranganatha VL
J Biomol Struct Dyn; 2022; 40(23):13032-13048. PubMed ID: 34632942
[TBL] [Abstract][Full Text] [Related]
6. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
[TBL] [Abstract][Full Text] [Related]
7. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
8. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
[TBL] [Abstract][Full Text] [Related]
10. Binding properties of selective inhibitors of P323L mutated RdRp of SARS-CoV-2: a combined molecular screening, docking and dynamics simulation study.
Chinnamadhu A; Ramakrishnan J; Suresh S; Poomani K
J Biomol Struct Dyn; 2024 May; 42(8):4283-4296. PubMed ID: 37301607
[TBL] [Abstract][Full Text] [Related]
11. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
12.
M RK; Gideon DA; Mariadasse R; Nirusimhan V; A SR; Edward JC; Jeyaraman J; Dhayabaran V
J Biomol Struct Dyn; 2022 Sep; 40(15):6710-6724. PubMed ID: 33615998
[TBL] [Abstract][Full Text] [Related]
13. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
Mosayebnia M; Hajiagha Bozorgi A; Rezaeianpour M; Kobarfard F
J Biomol Struct Dyn; 2022 Sep; 40(14):6569-6586. PubMed ID: 33599180
[TBL] [Abstract][Full Text] [Related]
14. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
15. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
16. Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective.
Sonousi A; Mahran HA; Ibrahim IM; Ibrahim MN; Elfiky AA; Elshemey WM
Pharmacol Rep; 2021 Dec; 73(6):1754-1764. PubMed ID: 34165771
[TBL] [Abstract][Full Text] [Related]
17. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
18. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
Tsuji M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
[TBL] [Abstract][Full Text] [Related]
19. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir analogs against SARS-CoV-2 RNA-dependent RNA polymerase.
Ahmed S; Mahtarin R; Islam MS; Das S; Al Mamun A; Ahmed SS; Ali MA
J Biomol Struct Dyn; 2022; 40(21):11111-11124. PubMed ID: 34315339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]